Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27633890 | 1.00 | KDM4E (0.50) | KDM4EL3MBTL1ADRB2AOC3CYP2D6 | |
| SCHEMBL20095130 | 0.82 | KDM4E (0.65) | KDM4EL3MBTL1ADRB2AOC3CYP2D6 | |
| SCHEMBL432726 | 0.82 | KDM4E (0.65) | KDM4EL3MBTL1ADRB2AOC3CYP2D6 | |
| SCHEMBL27685203 | 0.81 | ADRB2 (0.56) | KDM4EL3MBTL1ADRB2AOC3CYP2D6 | |
| SCHEMBL1664892 | 0.74 | IDO1 (0.35) | MAPK1 | |
| SCHEMBL28844101 | 0.74 | MAPT (0.33) | — | |
| SCHEMBL28292939 | 0.73 | ADRB2 (0.58) | KDM4EL3MBTL1ADRB2SMN1; SMN2ADRB1 | |
| SCHEMBL28333299 | 0.73 | LMNA (0.54) | KDM4EL3MBTL1ADRB2AOC3CYP2D6 | |
| SCHEMBL23004979 | 0.71 | ADRB2 (0.60) | KDM4EL3MBTL1ADRB2AOC3CYP2D6 | |
| SCHEMBL28335675 | 0.71 | MAPT (0.67) | KDM4EL3MBTL1ADRB2AOC3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100528835-C | Beta in crystalline form2Adrenergic receptor agonists | THERAVANCE INC (US) | 2009-08-19 | — | — | CN | disclosed |
| CN-100491342-C | Crystalline beta2Adrenergic receptor agonists | THERAVANCE INC (US) | 2009-05-27 | — | — | CN | disclosed |
| CN-1997623-A | Chemical process and novel crystalline forms | GLAXO GROUP LTD (GB) | 2007-07-11 | — | — | CN | disclosed |
| EP-1725525-A1 | DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| EP-1723108-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1723112-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1723110-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| CN-1795169-A | Beta in crystalline form2Adrenergic receptor agonists | THERAVANCE INC (US) | 2006-06-28 | — | — | CN | disclosed |
| WO-2005087736-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087722-A1 | DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087735-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087733-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| CN-1671650-A | Crystalline beta2Adrenergic receptor agonists | THERAVANCE INC (US) | 2005-09-21 | — | — | CN | disclosed |